You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

Jan Mattsson Biography and Net Worth

Insider of Albireo Pharma

Jan Mattsson has more than 20 years of experience in the pharmaceutical industry, covering a range of functions including R&D, business development, R&D operations and management. Prior to co-founding Albireo, he held various project leader and management positions at AstraZeneca, primarily in gastrointestinal R&D. Dr. Mattsson holds a B.Sc. in Chemistry and a Ph.D. in Biochemistry from University of Gothenburg.

What is Jan Mattsson's net worth?: The estimated net worth of Jan Mattsson is at least $2.56 million as of July 22nd, 2022. Dr. Mattsson owns 57,961 shares of Albireo Pharma stock worth more than $2,558,978 as of April 19th. This net worth estimate does not reflect any other investments that Dr. Mattsson may own. Learn More about Jan Mattsson's net worth.
How do I contact Jan Mattsson?: The corporate mailing address for Dr. Mattsson and other Albireo Pharma executives is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. Albireo Pharma can also be reached via phone at (857) 254-5555 and via email at [email protected]. Learn More on Jan Mattsson's contact information.
Has Jan Mattsson been buying or selling shares of Albireo Pharma?: Jan Mattsson has not been actively trading shares of Albireo Pharma over the course of the past ninety days. Most recently, Jan Mattsson sold 205 shares of the business's stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $24.68, for a transaction totalling $5,059.40. Following the completion of the sale, the insider now directly owns 57,961 shares of the company's stock, valued at $1,430,477.48. Learn More on Jan Mattsson's trading history.
Who are Albireo Pharma's active insiders?: Albireo Pharma's insider roster includes Ronald Cooper (CEO), Jason Duncan (Insider), Simon Harford (CFO), Patrick Horn (Insider), Jan Mattsson (Insider), and Pamela Stephenson (insider). Learn More on Albireo Pharma's active insiders.

Jan Mattsson Insider Trading History at Albireo Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/22/2022	Sell	205	$24.68	$5,059.40	57,961
3/3/2021	Sell	31,470	$36.85	$1,159,669.50
6/13/2018	Sell	25,000	$32.26	$806,500.00	43,538

Jan Mattsson Buying and Selling Activity at Albireo Pharma

Albireo Pharma Company Overview

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Today's Range

Now: $44.15

$43.99

$44.90

50 Day Range

MA: $44.17

$43.50

$44.95

2 Week Range

Now: $44.15

$16.02

$45.23

Volume

1,241,200 shs

Average Volume

704,539 shs

Market Capitalization

$913.91 million

P/E Ratio

N/A

Dividend Yield